NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

醫藥品受託製造、開發的全球市場 (∼2025年):各服務區分 (醫藥品、生技藥品、API等)、終端用戶 (大製藥、中小規模製藥、非專利製藥、CRO)、地區

Pharmaceutical Contract Development and Manufacturing Market (Pharmaceutical, Biologics, Active Pharma ingredients, tablet, Parenteral, Oral Liquid, Semi-Solids), End User (Big Pharma, Small Pharma, Generic Pharma,CRO)-Global Forecast to 2025

出版商 MarketsandMarkets 商品編碼 995931
出版日期 內容資訊 英文 192 Pages
訂單完成後即時交付
價格
醫藥品受託製造、開發的全球市場 (∼2025年):各服務區分 (醫藥品、生技藥品、API等)、終端用戶 (大製藥、中小規模製藥、非專利製藥、CRO)、地區 Pharmaceutical Contract Development and Manufacturing Market (Pharmaceutical, Biologics, Active Pharma ingredients, tablet, Parenteral, Oral Liquid, Semi-Solids), End User (Big Pharma, Small Pharma, Generic Pharma,CRO)-Global Forecast to 2025
出版日期: 2021年03月10日內容資訊: 英文 192 Pages
簡介

全球醫藥品受託製造、開發的市場規模在預測期間內預計以7.7%的年複合成長率發展,從2020年的1007億美元,成長到2025年1461億美元的規模。

對學名藥需求高漲,醫藥品R&D的投資增加,CDMO對高製造技術的投資,生技藥品的需求高漲,特殊醫藥品的關注高漲,核醫學領域的成長,細胞、基因治療的進步等要素預計促進該市場的成長。

本報告提供全球醫藥品受託製造、開發的市場調查,市場定義和概要,價值鏈,新型冠狀病毒感染疾病 (COVID-19) 以及其他的市場影響因素分析,法律制度,市場規模的變化、預測,服務、終端用戶、地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等彙整資訊。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

第5章 市場概要

  • 市場動態
    • 促進因素
    • 市場機會
    • 課題
    • 趨勢
  • 價值鏈分析
  • 生態系統
  • 供應鏈
  • COVID-19的影響
  • 法規評估
  • 波特的五力分析

第6章 市場分析、預測:各類服務

  • 醫藥品製造服務
    • API製造服務
    • FDF製造服務
  • 醫藥品開發服務
  • 生技藥品製造服務
    • 生物API製造服務
    • 生物FDF製造服務

第7章 市場分析、預測:各終端用戶

  • 大規模製藥企業
  • 中小規模製藥企業
  • 非專利製藥企業
  • 其他

第8章 市場分析、預測:各地區、主要國家

  • 歐洲
    • 德國
    • 義大利
    • 法國
    • 英國
    • 瑞士
    • 西班牙
    • 其他
  • 北美
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 其他
  • 南美
  • 中東、非洲

第9章 競爭情形

  • 概要
  • 主要企業的收益分配
  • 市場佔有率分析
  • 競爭領導製圖
  • Start-Ups/SME評估矩陣
  • 企業的服務足跡
  • 企業的地理足跡
  • 競爭模式

第10章 企業簡介

  • 主要企業
    • LONZA GROUP
    • THERMO FISHER SCIENTIFIC INC.
    • CATALENT
    • RECIPHARM AB
    • ABBVIE
    • SIEGFRIED HOLDING AG
    • EVONIK INDUSTRIES
    • BOEHRINGER INGELHEIM
    • PIRAMAL PHARMA SOLUTIONS
    • SAMSUNG BIOLOGICS
    • WUXI APPTEC (WUXI STA)
    • FUJIFILM HEALTHCARE
  • 其他企業
    • VETTER PHARMA INTERNATIONAL
    • FAMAR HEALTH CARE SERVICES
    • AENOVA GROUP
    • ALMAC GROUP
    • CAMBREX
    • CORDENPHARMA
    • BIOVECTRA
    • ALBANY MOLECULAR RESEARCH

第11章 附錄

目錄
Product Code: PH 7263

The global pharmaceutical contract development and manufacturing market is projected to reach USD 146.1 billion by 2025 from USD 100.7 billion in 2020, at a CAGR of 7.7% during the forecast period. Market growth is driven mainly by factors such as rising demand for generics, increasing investments in pharmaceutical R&D, and investments in advanced manufacturing technologies by CDMOs. The increasing demand for biological therapies, growing focus on specialty medicines, growth in the nuclear medicines sector, and advancements in cell and gene therapies are also expected to offer market growth opportunities in the coming years.

"The small and medium-sized pharmaceutical companies segment accounted for the highest growth rate in the pharmaceutical contract development and manufacturing market, byend user, during the forecast period"

The pharmaceutical contract development and manufacturing market is segmented intobig pharmaceutical companies, small & medium-sized pharmaceutical companies, generic pharmaceutical companies, and other end users.The small and medium-sized pharmaceutical companies segment accounted for the highest growth rate in the pharmaceutical contract development and manufacturing market in 2020. This segment's high growth can be attributed to the increasing number of emerging pharmaceutical companies that lack the in-house capabilities to manufacture and develop complex formulations and drug products.

"Biologics manufacturing services segment accounted for the highest CAGR"

Based on service, the pharmaceutical contract development and manufacturing market is segmented into pharmaceutical manufacturing, biologics manufacturing, and drug development services. In 2020, the biologics manufacturing servicessegment accounted for the highest growth rate. The major factor driving the growth of this segment is the growing demand for vaccines and biosimilars.

"Asia Pacific: The fastest-growing countryin thepharmaceutical contract development and manufacturing market"

Thepharmaceutical contract development and manufacturing market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is projected to register the highest CAGR during the forecast period. This growth can be attributed to factors such as growth in the manufacturing sector, favorable government regulations, growing strategic expansions from leading companies, increasing emphasis on off-patent drugs, and the presence of a highly skilled workforce.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 80%and Demand Side 20%
  • By Designation: C-level - 25%, D-level - 20%, and Others - 55%
  • By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%

Lists of Companies Profiled in the Report:

  • Thermo Fisher Scientific Inc. (US)
  • Catalent, Inc. (US)
  • Lonza Group Ltd. (Switzerland)
  • Recipharm AB (Sweden)
  • Siegfried Holding AG (Switzerland)
  • WuXiAppTec (China)
  • Samsung Biologics (South Korea)
  • Boehringer Ingelheim International GmbH (Germany)
  • Piramal Pharma Solutions (India)
  • Vetter Pharma International GmbH (Germany)
  • FAMAR Health Care Services (France)
  • AbbVie Inc. (US)
  • Aenova Group (Germany)
  • Almac Group (UK)
  • Evonik Industries AG (Germany)
  • Cambrex Corporation (US)
  • CordenPharma International (Germany)
  • Albany Molecular Research Inc. (AMRI) (US)
  • FUJIFILM Corporation (Japan)
  • BioVectra (Canada)

Research Coverage:

This report provides a detailed picture of thepharmaceutical contract development and manufacturing market. It aims at estimating the size and future growth potential of the market across different segments, such as the service, end user, and region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall pharmaceutical contract development and manufacturing marketand its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 1 BREAKDOWN OF PRIMARIES: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
    • 2.1.3 MARKET DATA ESTIMATION & TRIANGULATION
    • FIGURE 2 DATA TRIANGULATION METHODOLOGY
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • 2.2.1 MARKET SIZE ESTIMATION APPROACH
    • FIGURE 3 COMPANY REVENUE ANALYSIS-BASED ESTIMATION
    • FIGURE 4 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SIZE (USD BILLION): FINAL MARKET SIZE
  • 2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
    • FIGURE 5 FINAL CAGR PROJECTIONS (2020-2025)
  • 2.4 INSIGHTS FROM PRIMARIES
    • FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
  • 2.5 RESEARCH ASSUMPTIONS

3 EXECUTIVE SUMMARY

    • FIGURE 7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SHARE, BY SERVICE, 2019
    • FIGURE 8 BIOLOGICS MANUFACTURING SERVICES MARKET SHARE, BY TYPE, 2019
    • FIGURE 9 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2020 VS. 2025 (USD BILLION)
    • FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET

4 PREMIUM INSIGHTS

  • 4.1 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET OVERVIEW
    • FIGURE 11 GROWING DEMAND FOR GENERICS IS ONE OF THE KEY FACTORS DRIVING MARKET GROWTH
  • 4.2 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
    • FIGURE 12 PHARMACEUTICAL MANUFACTURING SERVICES TO COMMAND THE LARGEST SHARE OF THE EUROPEAN PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
  • 4.3 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER
    • FIGURE 13 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD
  • 4.4 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 14 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATES BETWEEN 2020 & 2025

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 15 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DRIVERS, OPPORTUNITIES, CHALLENGES, AND TRENDS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Patent expiry and increasing demand for generic drugs
      • 5.2.1.2 Increasing investments in pharmaceutical R&D
    • FIGURE 16 NUMBER OF PHARMA COMPANIES WITH ACTIVE DRUG PIPELINE PROJECTS (2010-2020)
    • FIGURE 17 GLOBAL R&D SPENDING (2016-2020)
      • 5.2.1.3 Investments in advanced manufacturing technologies by CDMOs
    • 5.2.2 OPPORTUNITIES
      • 5.2.2.1 Increasing demand for biological therapies
      • 5.2.2.2 Growth in the nuclear medicine sector
      • 5.2.2.3 Growing demand for cell and gene therapies
    • 5.2.3 CHALLENGES
      • 5.2.3.1 Introduction of serialization
    • 5.2.4 TRENDS
      • 5.2.4.1 Expansion in emerging countries
      • 5.2.4.2 CDMO industry consolidation
    • TABLE 1 LIST OF ACQUISITIONS
  • 5.3 VALUE CHAIN ANALYSIS
    • FIGURE 18 VALUE CHAIN ANALYSIS OF THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
  • 5.4 ECOSYSTEM MARKET MAP
    • FIGURE 19 ECOSYSTEM OF THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
  • 5.5 SUPPLY CHAIN
  • 5.6 IMPACT OF THE COVID-19 PANDEMIC ON THE GROWTH OF THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
    • TABLE 2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
    • 5.6.1 IMPACT ON THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
    • FIGURE 20 PRE-COVID VS. POST-COVID-19 SCENARIO, 2019-2021
  • 5.7 REGULATORY ASSESSMENT
    • 5.7.1 INTRODUCTION
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 THREAT OF NEW ENTRANTS
    • 5.8.2 THREAT OF SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF SUPPLIERS
    • 5.8.4 BARGAINING POWER OF BUYERS
    • 5.8.5 DEGREE OF COMPETITION

6 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE

  • 6.1 INTRODUCTION
    • TABLE 3 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
  • 6.2 PHARMACEUTICAL MANUFACTURING SERVICES
    • TABLE 4 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 5 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • 6.2.1 PHARMACEUTICAL API MANUFACTURING SERVICES
      • 6.2.1.1 Need to cut costs and ensure focus on core areas leads companies to outsource API manufacturing
    • TABLE 6 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • 6.2.2 PHARMACEUTICAL FDF MANUFACTURING SERVICES
    • TABLE 7 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 8 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
      • 6.2.2.1 Parenteral/injectable manufacturing services
        • 6.2.2.1.1 Need for high levels of expertise and growing drug development activities are driving the demand for contract manufacturing
    • TABLE 9 PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
      • 6.2.2.2 Tablet manufacturing services
        • 6.2.2.2.1 Shifting manufacturing requirements and the need to streamline production processes are driving market growth
    • TABLE 10 TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
      • 6.2.2.3 Capsule manufacturing services
        • 6.2.2.3.1 Growth in demand for capsule formulations has ensured growth opportunities for service providers
    • TABLE 11 CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
      • 6.2.2.4 Oral liquid manufacturing services
        • 6.2.2.4.1 Complexities involved in oral liquid manufacturing have prompted companies to opt for outsourcing
    • TABLE 12 ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
      • 6.2.2.5 Semi-solid manufacturing services
        • 6.2.2.5.1 Demand for specific manufacturing facilities to boost the outsourcing of semi-solids
    • TABLE 13 SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
      • 6.2.2.6 Other formulations manufacturing services
    • TABLE 14 OTHER FORMULATIONS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • 6.3 DRUG DEVELOPMENT SERVICES
    • 6.3.1 DRUG SUBSTANCE COMPLEXITY AND HIGH COSTS HAVE SUPPORTED THE OUTSOURCING OF DRUG DEVELOPMENT
    • TABLE 15 DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • 6.4 BIOLOGICS MANUFACTURING SERVICES
    • TABLE 16 BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 17 BIOLOGICS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • 6.4.1 BIOLOGICS API MANUFACTURING SERVICES
      • 6.4.1.1 Market for biologics API manufacturing is still in the nascent phase
    • TABLE 18 BIOLOGICS API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • 6.4.2 BIOLOGICS FDF MANUFACTURING SERVICES
      • 6.4.2.1 Increasing R&D costs and process complexity have prompted the shift toward contract manufacturing
    • TABLE 19 BIOLOGICS FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)

7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER

  • 7.1 INTRODUCTION
    • TABLE 20 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
  • 7.2 BIG PHARMACEUTICAL COMPANIES
    • 7.2.1 EMERGENCE OF NEW MEDICINES AND THERAPIES TO CONTRIBUTE TO THE GROWTH OF THIS MARKET
    • TABLE 21 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2025 (USD MILLION)
  • 7.3 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES
    • 7.3.1 GROWING DEVELOPMENT OF BIOLOGIC DRUGS AND HIGH PRICING PRESSURE TO BOOST MARKET GROWTH
    • TABLE 22 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2025 (USD MILLION)
  • 7.4 GENERIC PHARMACEUTICAL COMPANIES
    • 7.4.1 GROWING DEMAND FOR GENERICS TO SUPPORT MARKET GROWTH
    • TABLE 23 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2025 (USD MILLION)
  • 7.5 OTHER END USERS
    • TABLE 24 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2018-2025 (USD MILLION)

8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION

  • 8.1 INTRODUCTION
    • FIGURE 21 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GEOGRAPHICAL SNAPSHOT
    • TABLE 25 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION, 2018-2025 (USD MILLION)
  • 8.2 EUROPE
    • FIGURE 22 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT
    • TABLE 26 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 27 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 28 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 29 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 30 EUROPE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 31 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 8.2.1 GERMANY
      • 8.2.1.1 High healthcare expenditure and increased pharmaceutical production to support market growth
    • TABLE 32 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 33 GERMANY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 34 GERMANY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 35 GERMANY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 36 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 8.2.2 ITALY
      • 8.2.2.1 Increasing focus on clinical research and the growing popularity of branded drugs are driving the demand for contract development and manufacturing
    • TABLE 37 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 38 ITALY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 39 ITALY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 40 ITALY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 41 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 8.2.3 FRANCE
      • 8.2.3.1 Presence of leading pharmaceutical companies to support market growth in France
    • TABLE 42 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 43 FRANCE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 44 FRANCE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 45 FRANCE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 46 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 8.2.4 UK
      • 8.2.4.1 Growth in the generics market and the rising cost of manufacturing parenteral formulations are driving market growth
    • TABLE 47 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 48 UK: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 49 UK: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 50 UK: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 51 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 8.2.5 SWITZERLAND
      • 8.2.5.1 Large volume of pharmaceutical production and growing scope for generics to provide growth opportunities
    • TABLE 52 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 53 SWITZERLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 54 SWITZERLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 55 SWITZERLAND: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 56 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 8.2.6 SPAIN
      • 8.2.6.1 Increase in biologics production to support market growth
    • TABLE 57 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 58 SPAIN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 59 SPAIN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 60 SPAIN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 61 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 8.2.7 REST OF EUROPE
    • TABLE 62 ROE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 63 ROE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 64 ROE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 65 ROE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 66 ROE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
  • 8.3 NORTH AMERICA
    • TABLE 67 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 68 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 69 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 70 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 71 NORTH AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 72 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 8.3.1 US
      • 8.3.1.1 The US dominates the North American pharmaceutical contract development and manufacturing market
    • TABLE 73 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 74 US: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 75 US: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 76 US: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 77 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 8.3.2 CANADA
      • 8.3.2.1 Growth of the emerging markets and slowdown in new product approvals will hamper the market growth
    • TABLE 78 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 79 CANADA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 80 CANADA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 81 CANADA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 82 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
  • 8.4 ASIA PACIFIC
    • FIGURE 23 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT
    • TABLE 83 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 84 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 85 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 86 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 87 ASIA PACIFIC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 88 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 8.4.1 CHINA
      • 8.4.1.1 Favorable government regulations are fueling market growth in China
    • TABLE 89 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 90 CHINA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 91 CHINA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 92 CHINA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 93 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 8.4.2 INDIA
      • 8.4.2.1 Low manufacturing costs and a skilled workforce are factors attracting outsourcing and investment to India
    • TABLE 94 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 95 INDIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 96 INDIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 97 INDIA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 98 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 8.4.3 SOUTH KOREA
      • 8.4.3.1 Government investments are a key contributor to market growth in South Korea
    • TABLE 99 SOUTH KOREA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 100 SOUTH KOREA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 101 SOUTH KOREA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • 8.4.4 JAPAN
      • 8.4.4.1 Growing generics demand and government initiatives to drive the demand for contract manufacturing of drugs
    • TABLE 102 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 103 JAPAN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 104 JAPAN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 105 JAPAN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 106 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 8.4.5 REST OF ASIA PACIFIC
    • TABLE 107 ROAPAC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 108 ROAPAC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 109 ROAPAC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 110 ROAPAC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 111 ROAPAC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
  • 8.5 LATIN AMERICA
    • 8.5.1 FAVORABLE COST STRUCTURE AND GOVERNMENT INVESTMENTS TO DRIVE PHARMACEUTICAL PRODUCTION IN LATAM
    • TABLE 112 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 113 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 114 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 115 LATIN AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 116 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
  • 8.6 MIDDLE EAST & AFRICA
    • 8.6.1 GOVERNMENT SUPPORT TO BOOST LOCAL PRODUCTION IS EXPECTED TO OFFER GROWTH OPPORTUNITIES FOR CONTRACT MANUFACTURERS IN THE REGION
    • TABLE 117 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 118 MIDDLE EAST & AFRICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 119 MIDDLE EAST & AFRICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)

9 COMPETITIVE LANDSCAPE

  • 9.1 OVERVIEW
  • 9.2 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
  • 9.3 MARKET SHARE ANALYSIS
    • FIGURE 25 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET RANK, BY KEY PLAYER, 2019
    • TABLE 120 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DEGREE OF COMPETITION
  • 9.4 COMPETITIVE LEADERSHIP MAPPING
    • 9.4.1 STARS
    • 9.4.2 EMERGING LEADERS
    • 9.4.3 PERVASIVE PLAYERS
    • 9.4.4 PARTICIPANTS
    • FIGURE 26 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: COMPANY EVALUATION QUADRANT (2019)
  • 9.5 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: START-UP/SME EVALUATION MATRIX, 2019
    • 9.5.1 PROGRESSIVE COMPANIES
    • 9.5.2 STARTING BLOCKS
    • 9.5.3 RESPONSIVE COMPANIES
    • 9.5.4 DYNAMIC COMPANIES
    • FIGURE 27 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: STARTUP/SME EVALUATION MATRIX, 2019
  • 9.6 COMPANY SERVICE FOOTPRINT
    • TABLE 121 SERVICE PORTFOLIO ANALYSIS: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
  • 9.7 COMPANY GEOGRAPHIC FOOTPRINT OF MAJOR PLAYERS IN THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
    • TABLE 122 GEOGRAPHIC REVENUE MIX: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET (2019)
  • 9.8 COMPETITIVE SCENARIO
    • TABLE 123 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: SERVICE LAUNCHES, MAY 2019-OCTOBER 2020
    • TABLE 124 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DEALS, MARCH 2019-JANUARY 2021
    • TABLE 125 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: OTHERS, MAY 2019-NOVEMBER 2020

10 COMPANY PROFILES

  • (Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)**
  • 10.1 MAJOR PLAYERS
    • 10.1.1 LONZA GROUP
    • TABLE 126 LONZA GROUP: BUSINESS OVERVIEW
    • FIGURE 28 LONZA GROUP: COMPANY SNAPSHOT (2020)
    • TABLE 127 LONZA GROUP: SERVICES OFFERED
    • 10.1.2 THERMO FISHER SCIENTIFIC INC.
    • TABLE 128 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
    • FIGURE 29 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2019)
    • TABLE 129 THERMO FISHER SCIENTIFIC: SERVICES OFFERED
    • 10.1.3 CATALENT
    • TABLE 130 CATALENT: BUSINESS OVERVIEW
    • FIGURE 30 CATALENT: COMPANY SNAPSHOT (2020)
    • TABLE 131 CATALENT: SERVICES OFFERED
    • 10.1.4 RECIPHARM AB
    • TABLE 132 RECIPHARM AB: BUSINESS OVERVIEW
    • FIGURE 31 RECIPHARM AB: COMPANY SNAPSHOT (2019)
    • TABLE 133 RECIPHARM AB: SERVICES OFFERED
    • 10.1.5 ABBVIE
    • TABLE 134 ABBVIE: BUSINESS OVERVIEW
    • FIGURE 32 ABBVIE: COMPANY SNAPSHOT (2019)
    • TABLE 135 ABBVIE: SERVICES OFFERED
    • 10.1.6 SIEGFRIED HOLDING AG
    • TABLE 136 SIEGFRIED HOLDING AG: BUSINESS OVERVIEW
    • FIGURE 33 SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2019)
    • TABLE 137 SIEGFRIED HOLDING AG: SERVICES OFFERED
    • 10.1.7 EVONIK INDUSTRIES
    • TABLE 138 EVONIK INDUSTRIES: BUSINESS OVERVIEW
    • FIGURE 34 EVONIK INDUSTRIES: COMPANY SNAPSHOT (2019)
    • TABLE 139 EVONIK INDUSTRIES: SERVICES OFFERED
    • 10.1.8 BOEHRINGER INGELHEIM
    • TABLE 140 BOEHRINGER INGELHEIM: BUSINESS OVERVIEW
    • FIGURE 35 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2019)
    • TABLE 141 BOEHRINGER INGELHEIM: SERVICES OFFERED
    • 10.1.9 PIRAMAL PHARMA SOLUTIONS
    • TABLE 142 PIRAMAL PHARMA SOLUTIONS: BUSINESS OVERVIEW
    • FIGURE 36 PIRAMAL PHARMA SOLUTIONS: COMPANY SNAPSHOT (2019)
    • TABLE 143 PIRAMAL PHARMA SOLUTIONS: SERVICES OFFERED
    • 10.1.10 SAMSUNG BIOLOGICS
    • TABLE 144 SAMSUNG BIOLOGICS: BUSINESS OVERVIEW
    • FIGURE 37 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2019)
    • TABLE 145 SAMSUNG BIOLOGICS: SERVICES OFFERED
    • 10.1.11 WUXI APPTEC (WUXI STA)
    • TABLE 146 WUXI APPTEC: BUSINESS OVERVIEW
    • FIGURE 38 WUXI APPTEC: COMPANY SNAPSHOT (2019)
    • TABLE 147 WUXI APPTEC: SERVICES OFFERED
    • 10.1.12 FUJIFILM HEALTHCARE
    • TABLE 148 FUJIFILM HEALTHCARE: BUSINESS OVERVIEW
    • FIGURE 39 FUJIFILM HEALTHCARE: COMPANY SNAPSHOT (2019)
    • TABLE 149 FUJIFILM HEALTHCARE: SERVICES OFFERED
  • 10.2 OTHER PLAYERS
    • 10.2.1 VETTER PHARMA INTERNATIONAL
    • TABLE 150 VETTER PHARMA INTERNATIONAL: BUSINESS OVERVIEW
    • TABLE 151 VETTER PHARMA INTERNATIONAL: SERVICES OFFERED
    • 10.2.2 FAMAR HEALTH CARE SERVICES
    • TABLE 152 FAMAR HEALTH CARE SERVICES: BUSINESS OVERVIEW
    • TABLE 153 FAMAR HEALTH CARE SERVICES: SERVICES OFFERED
    • 10.2.3 AENOVA GROUP
    • TABLE 154 AENOVA GROUP: BUSINESS OVERVIEW
    • TABLE 155 AENOVA GROUP: SERVICES OFFERED
    • 10.2.4 ALMAC GROUP
    • 10.2.5 CAMBREX
    • 10.2.6 CORDENPHARMA
    • 10.2.7 BIOVECTRA
    • 10.2.8 ALBANY MOLECULAR RESEARCH
  • *Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

11 APPENDIX

  • 11.1 DISCUSSION GUIDE
  • 11.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 11.3 AVAILABLE CUSTOMIZATIONS
  • 11.4 RELATED REPORTS
  • 11.5 AUTHOR DETAILS 196